The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
A definitive model for predicting absolute risk of coronary heart disease (CHD) in male and female people with Type II diabetes is not yet available. This paper provides an equation for estimating the risk of new CHD events in people with Type II diabetes, based on data from 4540 U.K. Prospective Diabetes Study male and female patients. Unlike previously published risk equations, the model is diabetes-specific and incorporates glycaemia, systolic blood pressure and lipid levels as risk factors, in addition to age, sex, ethnic group, smoking status and time since diagnosis of diabetes. All variables included in the final model were statistically significant (P<0.001, except smoking for which P=0.0013) in likelihood ratio testing. This model provides the estimates of CHD risk required by current guidelines for the primary prevention of CHD in Type II diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The lower the CAD risk, the higher the chance of a false positive”
From Exercise and Type 2 Diabetes (2010) · cites this paper as [248]
In the citing paper
“During the entire follow-up period, the rate of death among patients in the conventionaltherapy group was 50%, a finding that underscores the poor prognosis for such patients in the absence of intensive treatment.20”
From Effect of a multifactorial intervention on mortality in type 2 diabetes (2008) · cites this paper as [20]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationStratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Self-citationPrevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
Cited by
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project
Conroy, R. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00114-3 · Cited by 5,290
“This excess risk of diabetic persons is in part explained by ‘diabetes-related’ factors, such as type and duration of diabetes, glycaemic control, and presence of retinopathy or microalbuminuria or proteinuria.(53)”
BackgroundMethodCosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
FRAX™ and the assessment of fracture probability in men and women from the UK
Kanis, J. A., Johnell, O., Oden, A., Johansson, H., & McCloskey, E. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0543-5 · Cited by 2,467
The Metabolic Syndrome: Time for a Critical Appraisal
Kahn, R., Buse, J., Ferrannini, E., & Stern, M. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2289 · Cited by 2,378
“This fact is highlighted in other algorithms used to pred ic t CVD r i sk us ing regres s ion coefficients to assign different weights to risk factors (95,99), and it is apparent from studies that examined the risk of CVD in persons with one or two components of the syndrome versus three or more (97).”
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
Colberg, S. R., Sigal, R. J., Fernhall, B., Regensteiner, J. G., Blissmer, B. J., Rubin, R. R., Chasan-Taber, L., Albright, A. L., & Braun, B. (2010) · Diabetes Care · doi:10.2337/dc10-9990 · Cited by 1,955
“htm) (248) can also be used to calculate expected 10-year CV risk based on age, sex, smoking, A1C, diabetes duration, lipids, BP, and race.”
Adler, A. I., Stevens, R. J., Manley, S. E., Bilous, R. W., Cull, C. A., Holman, R. R., & UKPDS Group (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00712.x · Cited by 1,816
Self-citationRisk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Sattar, N., Eliasson, B., Svensson, A.-M., Zethelius, B., Miftaraj, M., McGuire, D. K., Rosengren, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800256 · Cited by 1,475
Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2
Hippisley-Cox, J., Coupland, C., Vinogradova, Y., Robson, J., Minhas, R., Sheikh, A., & Brindle, P. (2008) · BMJ · doi:10.1136/bmj.39609.449676.25 · Cited by 1,459
Standards of Medical Care in Diabetes—2008
Dora, J. M., Kramer, C. K., & Canani, L. H. (2008) · Diabetes Care · doi:10.2337/dc08-0109 · Cited by 1,409
“There were 24.8 and 13.8% low-risk, 27.2 and 24.8% intermediate-risk, and 48.1 and 61.4% high-risk patients by UK Prospective Diabetes Study Risk Engine and Framingham Risk Score criteria, respectively.”
InfluentialWilliams, B., Poulter, N. R., Brown, M. J., Davis, M., McInnes, G. T., Potter, J. F., Sever, P. S., & McG Thom, S. (2004) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001683 · Cited by 1,272
Prepared by: British Cardiac Society, B. H. S. (2005) · Heart · doi:10.1136/hrt.2005.079988 · Cited by 1,216
Risk prediction models: II. External validation, model updating, and impact assessment
Moons, K. G. M., Kengne, A. P., Grobbee, D. E., Royston, P., Vergouwe, Y., Altman, D. G., & Woodward, M. (2012) · Heart · doi:10.1136/heartjnl-2011-301247 · Cited by 1,195
“equations The UK Prospective Diabetes Study (UKPDS) CHD equation has been designed for risk evaluation for any duration of followup in a patient with newly diagnosed type 2 diabetes, or who has had diabetes for a known length of time.(30) The Framingham Anderson CHD equation has been developed from data of individuals…”
MethodJellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus
Buse, J. B., Ginsberg, H. N., Bakris, G. L., Clark, N. G., Costa, F., Eckel, R., Fonseca, V., Gerstein, H. C., Grundy, S., Nesto, R. W., et al. (2007) · Diabetes Care · doi:10.2337/dc07-9917 · Cited by 1,055
Achievement of Goals in U.S. Diabetes Care, 1999–2010
Ali, M. K., Bullard, K. M., Saaddine, J. B., Cowie, C. C., Imperatore, G., & Gregg, E. W. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1213829 · Cited by 979
Physical Activity/Exercise and Type 2 Diabetes
Sigal, R. J., Kenny, G. P., Wasserman, D. H., Castaneda-Sceppa, C., & White, R. D. (2006) · Diabetes Care · doi:10.2337/dc06-9910 · Cited by 949
“Prosepctive Diabetes Study) Risk Engine (50) (http://www.”
Booth, G. L., Kapral, M. K., Fung, K., & Tu, J. V. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68967-8 · Cited by 783
Davies, M. J., Heller, S., Skinner, T. C., Campbell, M. J., Carey, M. E., Cradock, S., Dallosso, H. M., Daly, H., Doherty, Y., Eaton, S., et al. (2008) · BMJ · doi:10.1136/bmj.39474.922025.be · Cited by 760
“Although the risk estimate for cardiovascular disease from the United Kingdom prospective diabetes study”
BackgroundPhysical Activity/Exercise and Type 2 Diabetes
Sigal, R. J., Kenny, G. P., Wasserman, D. H., & Castaneda-Sceppa, C. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2518 · Cited by 763
“For example, a 38-year-old Caucasian nonsmoking man with diabetes for 5 years, HbA1c 7.5%, systolic blood pressure 130 mmHg, total cholesterol 5.2 mmol/l, and HDL cholesterol 1.1 mmol/l would have a 10-year CAD risk of only 7.3% or ~0.7% per year, calculated using the U.K. Prospective Diabetes Study (UKPDS) Risk Engin…”
BackgroundInfluentialHerman, W. H., Hoerger, T. J., Brandle, M., Hicks, K., Sorensen, S., Zhang, P., Hamman, R. F., Ackermann, R. T., Engelgau, M. M., Ratner, R. E., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-5-200503010-00007 · Cited by 703
Metabolic Syndrome: A Multiplex Cardiovascular Risk Factor
Grundy, S. M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0513 · Cited by 658
Buse, J. B., Ginsberg, H. N., Bakris, G. L., Clark, N. G., Costa, F., Eckel, R., Fonseca, V., Gerstein, H. C., Grundy, S., Nesto, R. W., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.179294 · Cited by 638
Young, B. A., Lin, E. H. B., Korff, M. V., Simon, G., Ciechanowski, P. S., Ludman, E. J., Everson‐Stewart, S., Kinder, L. S., Oliver, M. M., Boyko, E. J., et al. (2008) · PubMed · Cited by 686
Clarke, P. M., Gray, A. M., Briggs, A., Farmer, A. J., Fenn, P., Stevens, R. J., Matthews, D. R., Stratton, I. M., Holman, R. R., & on behalf of the UK Prospective Diabetes Study (UKPDS) Group (2004) · Diabetologia · doi:10.1007/s00125-004-1527-z · Cited by 615
“The UKPDS Risk Engine, a risk calculator for estimating absolute risk of coronary heart disease [10] and stroke [11], has been developed based on factors such as age, sex, race, smoking status, and levels of HbA1c, systolic BP and lipid ratios in the first 2 years after diagnosis of Type 2 diabetes.”
BackgroundSelf-citation(2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.10.013 · Cited by 609
Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab154 · Cited by 542
(2010) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181eeb61c · Cited by 567
“The lower the CAD risk, the higher the chance of a false positive (79,248).”
A systematic review and economic evaluation of statins for the prevention of coronary events
Ward, S., Lloyd Jones, M., Pandor, A., Holmes, M., Ara, R., Ryan, A., Yeo, W., & Payne, N. (2007) · Health Technology Assessment · doi:10.3310/hta11140 · Cited by 556
Palmer, A. J., Roze, S., Valentine, W. J., Minshall, M. E., Foos, V., Lurati, F. M., Lammert, M., & Spinas, G. A. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x1980 · Cited by 526
“The risk model from the UKPDS risk engine is diabetes-specific and takes into account HbA 1c , SBP, lipid levels (total cholesterol to HDL ratio), age, sex, smoking status, race, and time since diagnosis of diabetes to calculate the probability of the first MI 44 .”
MethodJackson, R., Lawes, C. M., Bennett, D. A., Milne, R. J., & Rodgers, A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17833-7 · Cited by 519
Hayes, A. J., Leal, J., Gray, A. M., Holman, R. R., & Clarke, P. M. (2013) · Diabetologia · doi:10.1007/s00125-013-2940-y · Cited by 495
Self-citationCardiovascular risk in diabetes mellitus: Epidemiology, assessment and prevention
Wong, N. D., & Sattar, N. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00877-z · Cited by 495
D'Aiuto, F., Gkranias, N., Bhowruth, D., Khan, T., Orlandi, M., Suvan, J., Masi, S., Tsakos, G., Hurel, S., Hingorani, A. D., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30038-x · Cited by 473
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435
“Table 1 AACE Lipid Targets for Patients with Type 2 Diabetes (188,189,197,200,240-251)”
BackgroundKothari (2002) · doi:10.1161/01.str.0000020091.07144.c7 · Cited by 420
Self-citationProjecting the Future Diabetes Population Size and Related Costs for the U.S.
Huang, E. S., Basu, A., O'Grady, M., & Capretta, J. C. (2009) · Diabetes Care · doi:10.2337/dc09-0459 · Cited by 414
“Prediction models for all major diabetes-related complications have been developed by the UKPDS study group (7,8).”
BackgroundAnand, D. V., Lim, E., Hopkins, D., Corder, R., Shaw, L. J., Sharp, P., Lipkin, D., & Lahiri, A. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi808 · Cited by 392
Kahn, R., Buse, J., Ferrannini, E., & Stern, M. (2005) · Diabetologia · doi:10.1007/s00125-005-1876-2 · Cited by 376
“This problem stands in contrast to the Framingham [95] and UKPDS [99] risk models, in which the spectrum of severities is weighted, so that it is clear who may be at greater or lesser risk.”
InfluentialInflammation as a Link between Obesity and Metabolic Syndrome
Emanuela, F., Grazia, M., Marco, D. R., Maria Paola, L., Giorgio, F., & Marco, B. (2012) · Journal of Nutrition and Metabolism · doi:10.1155/2012/476380 · Cited by 357
Fitchett, D., Inzucchi, S. E., Cannon, C. P., McGuire, D. K., Scirica, B. M., Johansen, O. E., Sambevski, S., Kaspers, S., Pfarr, E., George, J. T., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037778 · Cited by 351
Stratton, I. M., Cull, C. A., Adler, A. I., Matthews, D. R., Neil, H. A. W., & Holman, R. R. (2006) · Diabetologia · doi:10.1007/s00125-006-0297-1 · Cited by 360
Self-citationOkamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 302
Quinn, R. R., Hemmelgarn, B. R., Padwal, R. S., Myers, M. G., Cloutier, L., Bolli, P., McKay, D. W., Khan, N. A., Hill, M. D., Mahon, J., et al. (2010) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(10)70378-0 · Cited by 346
SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe
SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration, Pennells, L., Kaptoge, S., Østergaard, H. B., Read, S. H., Carinci, F., Franch-Nadal, J., Petitjean, C., Taylor, O., Hageman, S. H. J., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad260 · Cited by 329
“statistically adapted) to reflect the substantial variation in CVD rates across different European countries.(1,10,11) To address these limitations, the ESC has convened an effort to extend the regionally recalibrated European SCORE2 10-year risk models,(12) enabling use in individuals with type 2 diabetes.”
BackgroundBalducci, S. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.380 · Cited by 329
Kwong, R. Y., Sattar, H., Wu, H., Vorobiof, G., Gandla, V., Steel, K., Siu, S., & Brown, K. A. (2008) · Circulation · doi:10.1161/circulationaha.107.727826 · Cited by 329
McPherson, R., Frohlich, J., Fodor, G., & Genest, J. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70310-5 · Cited by 308
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2019) · Endocrine Practice · doi:10.4158/cs-2018-0535 · Cited by 297
“Patients with diabetes, therefore, can be classified as high risk, very-high risk, or extreme risk; as such, the AACE recommends LDL-C targets of <100 mg/dL, <70 mg/dL, and <55 mg/dL; non-HDL-C targets of <130 mg/ dL, <100 mg/dL, and <80 mg/dL; and apo B targets of <90 mg/dL, <80 mg/dL, and 70 mg/dL, respectively, wit…”
BackgroundRisk Factors for Myocardial Infarction Case Fatality and Stroke Case Fatality in Type 2 Diabetes
Stevens, R. J., Coleman, R. L., Adler, A. I., Stratton, I. M., Matthews, D. R., & Holman, R. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.201 · Cited by 295
Self-citationEckel, R. H., Kahn, R., Robertson, R. M., & Rizza, R. A. (2006) · Circulation · doi:10.1161/circulationaha.106.176583 · Cited by 285
Validation of the CORE Diabetes Model Against Epidemiological and Clinical Studies
Palmera, A. J., Rozea, S., Valentinea, W. J., Minshallb, M. E., Foosa, V., Luratia, F. M., Lammerta, M., & Spinasc, G. A. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x2006 · Cited by 284
Lifetime Direct Medical Costs of Treating Type 2 Diabetes and Diabetic Complications
Zhuo, X., Zhang, P., & Hoerger, T. J. (2013) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2013.04.017 · Cited by 272
Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity
Cohen, R. V., Pinheiro, J. C., Schiavon, C. A., Salles, J. E., Wajchenberg, B. L., & Cummings, D. E. (2012) · Diabetes Care · doi:10.2337/dc11-2289 · Cited by 282
Alshehry, Z. H., Mundra, P. A., Barlow, C. K., Mellett, N. A., Wong, G., McConville, M. J., Simes, J., Tonkin, A. M., Sullivan, D. R., Barnes, E. H., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.023233 · Cited by 268
Guidelines for Computer Modeling of Diabetes and Its Complications
American Diabetes Association Consensus Panel (2004) · Diabetes Care · doi:10.2337/diacare.27.9.2262 · Cited by 270
Chaitman, B. R., Hardison, R. M., Adler, D., Gebhart, S., Grogan, M., Ocampo, S., Sopko, G., Ramires, J. A., Schneider, D., Frye, R. L., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.913111 · Cited by 263
“5–7,10–13 Briefly, the BARI 2D is a large international trial testing 2 major strategies in a 2 2 factorial design: (1) an early versus only if necessary revascularization strategy (revascularization versus IMT); and (2) a glycemic control strategy (IS versus IP therapy to a target glycohemoglobin A1c [HbA1c] of 7%).”
MethodElkeles, R. S., Godsland, I. F., Feher, M. D., Rubens, M. B., Roughton, M., Nugara, F., Humphries, S. E., Richmond, W., Flather, M. D., & for the PREDICT Study Group (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn279 · Cited by 261
“Methods are established for assignment of individual risk based on the major risk factors: age, gender, family history, smoking history, blood pressure, diabetes, and lipid profile.(3,4) Diabetes is now considered a CHD equivalent and patients with T2DM are offered cardiovascular risk reduction.”
BackgroundMonami, M., Ahrén, B., Dicembrini, I., & Mannucci, E. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12000 · Cited by 259
Gillett, M., Dallosso, H. M., Dixon, S., Brennan, A., Carey, M. E., Campbell, M. J., Heller, S., Khunti, K., Skinner, T. C., & Davies, M. J. (2010) · BMJ · doi:10.1136/bmj.c4093 · Cited by 250
“The UKPDS coronary heart disease and stroke risk engines use smoking status at diagnosis of diabetes as a risk factor.”
BackgroundHandelsman, Y., Jellinger, P. S., Guerin, C. K., Bloomgarden, Z. T., Brinton, E. A., Budoff, M. J., Davidson, M. H., Einhorn, D., Fazio, S., Fonseca, V. A., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2020-0490 · Cited by 248
Computer Modeling of Diabetes and Its Complications
The Mount Hood 4 Modeling Group (2007) · Diabetes Care · doi:10.2337/dc07-9919 · Cited by 199
“Source data for the model have been taken from DCCT and UKPDS report 64 for nephropathy, and from UKPDS reports 56 and 60 for macrovascular complications (3,4,21,25).”
BackgroundMethodYerramasu, A., Dey, D., Venuraju, S., Anand, D. V., Atwal, S., Corder, R., Berman, D. S., & Lahiri, A. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.09.041 · Cited by 240
Validation of the IMS CORE Diabetes Model
McEwan, P., Foos, V., Palmer, J. L., Lamotte, M., Lloyd, A., & Grant, D. (2014) · Value in Health · doi:10.1016/j.jval.2014.07.007 · Cited by 235
Vistisen, D., Andersen, G. S., Hansen, C. S., Hulman, A., Henriksen, J. E., Bech-Nielsen, H., & Jørgensen, M. E. (2016) · Circulation · doi:10.1161/circulationaha.115.018844 · Cited by 229
The Effectiveness of Pharmacist Interventions on Cardiovascular Risk
Tsuyuki, R. T., Al Hamarneh, Y. N., Jones, C. A., & Hemmelgarn, B. R. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.528 · Cited by 209
“Our system used the appropriate risk engine on the basis of the patient’s medical history: the UKPDS (United Kingdom Prospective Diabetes Study) risk engine (21) for patients with diabetes, the International model for prediction of recurrent CVD (22) for those with previous vascular disease, and the Framingham risk sc…”
Engagement in a Diabetes Self-management Website: Usage Patterns and Generalizability of Program Use
Glasgow, R. E., Christiansen, S. M., Kurz, D., King, D. K., Woolley, T., Faber, A. J., Estabrooks, P. A., Strycker, L., Toobert, D., & Dickman, J. (2011) · Journal of Medical Internet Research · doi:10.2196/jmir.1391 · Cited by 219
“The formula predicts occurrence of new heart disease in people with type 2 diabetes and incorporates hemoglobin A1c, systolic blood pressure, and lipid levels along with age, sex, race, smoking status, and time since diabetes diagnosis [37].”
van Dieren, S., Beulens, J. W. J., Kengne, A. P., Peelen, L. M., Rutten, G. E. H. M., Woodward, M., van der Schouw, Y. T., & Moons, K. G. M. (2012) · Heart · doi:10.1136/heartjnl-2011-300734 · Cited by 216
Ali, M. K., Bullard, K. M., Saydah, S., Imperatore, G., & Gregg, E. W. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30027-5 · Cited by 208
“1016/S2213-8587(18)30027-5 Permanent URL: https://pid.”
BackgroundMethodPaul, S., Ali, A., & Katare, R. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107613 · Cited by 199
Stefan, N., & Schulze, M. B. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00086-4 · Cited by 215
Malik, S., Zhao, Y., Budoff, M., Nasir, K., Blumenthal, R. S., Bertoni, A. G., & Wong, N. D. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.4191 · Cited by 215
Pousinho, S., Morgado, M., Falcão, A., & Alves, G. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.5.493 · Cited by 199
Singh, M., Kumar, A., Khanna, N. N., Laird, J. R., Nicolaides, A., Faa, G., Johri, A. M., Mantella, L. E., Fernandes, J. F. E., Teji, J. S., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102660 · Cited by 163
Rosenzweig, J. L., Ferrannini, E., Grundy, S. M., Haffner, S. M., Heine, R. J., Horton, E. S., & Kawamori, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0222 · Cited by 194
“The UKPDS risk engine has been developed with validated CVD risk estimates for people with T2DM (22, 23), but the population with previously diagnosed diabetes is outside the framework of the primary prevention population considered in this guideline.”
MethodColeman, R. L., Stevens, R. J., Retnakaran, R., & Holman, R. R. (2007) · Diabetes Care · doi:10.2337/dc06-1358 · Cited by 193
Self-citationEffect of a Pharmaceutical Care Program on Vascular Risk Factors in Type 2 Diabetes
Clifford, R. M., Davis, W. A., Batty, K. T., & Davis, T. M. E. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.771 · Cited by 188
Anand, D. V., Lahiri, A., Lim, E., Hopkins, D., & Corder, R. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.12.054 · Cited by 193
Brown, A. F., Gregg, E. W., Stevens, M. R., Karter, A. J., Weinberger, M., Safford, M. M., Gary, T. L., Caputo, D. A., Waitzfelder, B., Kim, C., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.12.2864 · Cited by 191
Kramer, C. K., Zinman, B., Gross, J. L., Canani, L. H., Rodrigues, T. C., Azevedo, M. J., & Retnakaran, R. (2013) · BMJ · doi:10.1136/bmj.f1654 · Cited by 194
RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020
Madhu, S., Chawla, R., Makkar, B., Ghosh, S., Saboo, B., & Kalra, S. (2020) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_225_20 · Cited by 167
“• QRISK3 Risk Score[541,542] • UKPDS Risk Engine.”
BackgroundCardiovascular risk assessment scores for people with diabetes: a systematic review
Chamnan, P., Simmons, R. K., Sharp, S. J., Griffin, S. J., & Wareham, N. J. (2009) · Diabetologia · doi:10.1007/s00125-009-1454-0 · Cited by 176
“engine (UKPDS 56) [ 47 ] 4,540 men and women aged 25–65 years with diabetes, without history of MI, angina or heart failure (UK) Newly physician-diagnosed diabetes and FPG >6 mmol/l on two further occasions Median”
BackgroundMethodInfluentialRisk Prediction of Cardiovascular Disease in Type 2 Diabetes
Cederholm, J., Eeg-Olofsson, K., Eliasson, B., Zethelius, B., Nilsson, P. M., Gudbjörnsdottir, S., & Register, O. B. O. T. S. N. D. (2008) · Diabetes Care · doi:10.2337/dc08-0662 · Cited by 173
“The UK Prospective Diabetes Study (UKPDS) risk engine is a diabetes-specific model for estimation of the absolute 10-year risk of myocardial infarction (6), stroke (7), and CVD (8) in patients with newly detected type 2 diabetes with onset age up to 65 years and includes A1C and diabetes duration as risk factor variab…”
BackgroundDeterminants of Progression of Coronary Artery Calcification in Type 2 Diabetes
Anand, D. V., Lim, E., Darko, D., Bassett, P., Hopkins, D., Lipkin, D., Corder, R., & Lahiri, A. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.08.032 · Cited by 170
Lutgers, H. L., Gerrits, E. G., Graaff, R., Links, T. P., Sluiter, W. J., Gans, R. O., Bilo, H. J., & Smit, A. J. (2009) · Diabetologia · doi:10.1007/s00125-009-1308-9 · Cited by 174
Guzder, R. N., Gatling, W., Mullee, M. A., Mehta, R. L., & Byrne, C. D. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01494.x · Cited by 174
Metabolic Syndrome: From Global Epidemiology to Individualized Medicine
Batsis, J. A., Nieto-Martinez, R. E., & Lopez-Jimenez, F. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100355 · Cited by 170
Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease
Luvai, A., Mbagaya, W., Hall, A. S., & Barth, J. H. (2012) · Clinical Medicine Insights Cardiology · doi:10.4137/cmc.s4324 · Cited by 189
Cardiac risk factors in patients with diabetes mellitus and major depression
Katon, W. J., Lin, E. H. B., Russo, J., Korff, M., Ciechanowski, P., Simon, G., Ludman, E., Bush, T., & Young, B. (2004) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2004.30405.x · Cited by 172
The DECODE Study Group, & on behalf of the European Diabetes Epidemiology Group (2004) · Diabetologia · doi:10.1007/s00125-004-1574-5 · Cited by 167
de Vos, A. F., Klaren, V. N. A., & Kijlstra, A. (1994) · PubMed · Cited by 180
Lin, Y.-K., Chen, H., Brown, R. A., Li, S.-H., & Yang, H.-J. (2017) · MIS Quarterly · doi:10.25300/misq/2017/41.2.07 · Cited by 158
“However, UKPDS seems to be the best model in predicting AMI, showing the merits of clinical trials in building certain risk models.”
BackgroundMethodInfluentialHuang, E. S., Zhang, Q., Gandra, N., Chin, M. H., & Meltzer, D. O. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-1-200807010-00005 · Cited by 165
Hutchins, V., Zhang, B., Fleurence, R. L., Krishnarajah, G., & Graham, J. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.570745 · Cited by 164
Wee, H. L., Cheung, Y., Li, S., Fong, K., & Thumboo, J. (2005) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-3-2 · Cited by 193
Balducci, S., D’Errico, V., Haxhi, J., Sacchetti, M., Orlando, G., Cardelli, P., Vitale, M., Bollanti, L., Conti, F., Zanuso, S., et al. (2019) · JAMA · doi:10.1001/jama.2019.0922 · Cited by 158
“a Based on the United Kingdom Prospective Diabetes Study (UKPDS) risk engine, which is based on the outcomes from 53000 patient-years of data in the UKPDS.(22) In theory, the 10-year risk for eachmeasure can range from0% to 100%, although themaximum risk for fatal stroke is below 50%.”
MethodInfluential
Metadata
- Authors
- STEVENS, R. J., KOTHARI, V., ADLER, A. I., & STRATTON, I. M.
- Affiliations
- University of Oxford (GB)
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2001-12-01
- Volume
- 101
- Issue
- 6
- Pages
- 671
- ISSN
- 0143-5221 (ISSN-L)
- OpenAlex
- W2117191092
- Cited by
- 1,084
- References
- 51
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 10 · 2023: 33 · 2022: 44 · 2021: 60 · 2020: 46 · 2019: 42 · 2018: 47 · 2017: 42 · 2016: 39 · 2015: 60 · 2014: 66 · 2013: 68 · 2012: 59
- FWCI
- 12.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- coronary artery disease, type 2 diabetes, cardiovascular risk prediction, risk prediction model, glycemia, systolic blood pressure, serum lipids, primary prevention, smoking, sex differences
- MeSH terms
- Adult, Blood Pressure, Coronary Disease, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Lipids, Male, Middle Aged, Risk Factors, Smoking, Models, Statistical, Survival Rate, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.